Skip to main content

Psoriatic arthritis

RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.




  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.



Rheumatic and autoimmune patients were not

Read Article
Psoriasis, arms, PsA

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

Jan 12, 2022

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Read Article
NICE (UK) has recommended upadacitinib for use in active Psoriatic Arthritis, 15 mg qd +/- MTX, in pts not responding to DMARDS. UPA can now be used in England Wales and Scotland https://t.co/JFxMrgjrUe

Dr. John Cush @RheumNow( View Tweet )

Jan 10, 2022
ICYMI: Cosentyx (secukinumab) was FDA approved for use in pediatric psoriatic arthritis & enthesitis-related arthritis, based on results of the ph III JUNIPERA study. Dosing based on weight (SEC 75 mg sc if 15-50kg; SEC 150 mg sc if 50 kg or more) https://t.co/S6mQmwKT1X

Dr. John Cush @RheumNow( View Tweet )

Jan 09, 2022
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit!https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c
Dr. John Cush @RheumNow( View Tweet )
Jan 07, 2022
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2022
psor.elb_.jpg

Spesolimab, an IL-36 Blocker, in Pustular Psoriasis

Jan 03, 2022

The NEJM has published the results of a phase 2 randomized trial showing that the use of an interleukin-36 receptor inhibitor, spesolimab, resulted in rapid improvement of generalized pustular psoriasis (at 1 week), but that adverse events and infections were of concern with 12 weeks of

Read Article
Best of 2021: Abbvie has released data from KEEPsAKE-1 and KEEPsAKE-2 studies (1407 pts) showing Risankizumab (IL--23 inhibitor) is effective in Psoriatic arthritis; RIS Rx pts achieved ACR20 of 57% and 51% at week 24 (vs PBO 34% and 27%; p<0.001) https://t.co/0C07aTlEQY

Dr. John Cush @RheumNow( View Tweet )

Dec 30, 2021
FDA.Safety.jpg

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

Dec 30, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

Dec 29, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
COVID vaccine vials

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

Dec 28, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
Patient Medication Preferences in PsAhttps://t.co/I1DXCFPNcf https://t.co/cqMGIJwLbA
Dr. John Cush @RheumNow( View Tweet )
Dec 24, 2021
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually!https://t.co/py6Gp8sPh8

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
fetus,defect,baby,malformation

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Dec 23, 2021

HCQ is one of the safest meds used in rheumatology, but new claims data suggests a small increase in the risk of malformations associated with first-trimester HCQ use. The March 2021 issue of the American Journal of Obstetrics and Gynecology studied the risk of major congenital malformations

Read Article
Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
FDA%20approved.jpg (keep)

Rinvoq FDA Approved for Active Psoriatic Arthritis

Dec 14, 2021

The FDA has approved upadacitinib (Rinvoq) today for use in the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.



The FDA approval is based on two pivotal Phase 3 trials,

Read Article
RheumNow Podcast square

T2T Debate - A Prologue with Dr. Marty Bergman

Dec 10, 2021

Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.



Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.



You can register and learn more about the meeting at:

Read Article
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/tl3Nkxdv0B https://t.co/WwxgWGuVcC
Dr. John Cush @RheumNow( View Tweet )
Dec 10, 2021
CBD and Opioids in PsA : Dr. Eric Ruderman ( @JointMD) reviews abstract #1456 and #1777 presented at the ACR21 annual meeting.https://t.co/ZATSfzqj51 https://t.co/dhFwgS9b6J
Dr. John Cush @RheumNow( View Tweet )
Dec 10, 2021
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

Dec 08, 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?



The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of

Read Article
FDA.Safety.jpg

FDA Puts Boxed Warnings on JAK Inhibitors

Dec 06, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
×